Immune biomarkers in irritable bowel syndrome: a review

References

• Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Dumitrascu DL. Rome III: new standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15(3):237–241.
   PubMedGoogle Scholar
• Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology. 2003;124(6):1662–1671.
   Web of Science ®Google Scholar
• Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997;314(7083):779–782.
   Google Scholar
• Spiller R, Lam C. An Update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil. 2012;18(3):258–268.
   PubMed Web of Science ®Google Scholar
• Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet. 1996;347(8995):150–153.
   PubMed Web of Science ®Google Scholar
• Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131(2):445–450; quiz 660.
   PubMed Web of Science ®Google Scholar
• Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009;136(6):1979–1988.
   PubMed Web of Science ®Google Scholar
• Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–721. e4.
   PubMed Web of Science ®Google Scholar
• Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;101(4):927–934.
   PubMed Web of Science ®Google Scholar
• Russo MW, Gaynes BN, Drossman DA. A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterol. 1999;29(4):339–343.
   PubMed Web of Science ®Google Scholar
• Martin R, Barron JJ, Zacker C. Irritable bowel syndrome: toward a cost- effective management approach. Am JManag Care. 2001;7(Suppl 8): S268–S275.
   PubMed Web of Science ®Google Scholar
• Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500–1511.
   PubMed Web of Science ®Google Scholar
• American Gastroenterological Association. The Burden of Gastrointestinal Diseases: 2001. Bethesda, MD: American Gastroenterological Association; 2001:1–86.
   Google Scholar
• Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther. 2004;20 Suppl 7:31–39.
   Google Scholar
• Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion? : a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010;105(4):848–858.
   Web of Science ®Google Scholar
• Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx. 2004;1(2):189–195.
   PubMedGoogle Scholar
• Clarke G, Quigley EM, Cryan JF, Dinan TG. Irritable bowel syndrome: towards biomarker identification. Trends Mol Med. 2009;15(10):478–489.
   Web of Science ®Google Scholar
• Lembo AJ, Neri B, Tolley J, Barken D, Carroll S, Pan H. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29(8):834–842.
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46(4):421–431.
   PubMed Web of Science ®Google Scholar
• Spiller R, Lam C. The shifting interface between IBS and IBD. Curr Opin Pharmacol. 2011;11(6):586–592.
   Web of Science ®Google Scholar
• Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol. 2009;104(2):392–400.
   PubMed Web of Science ®Google Scholar
• Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut. 2008;57(4):468–473.
   PubMed Web of Science ®Google Scholar
• Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122(7):1778–1783.
   PubMed Web of Science ®Google Scholar
• Ohman L, Isaksson S, Lundgren A, Simren M, Sjovall H. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3(10):980–986.
   Web of Science ®Google Scholar
• Ohman L, Isaksson S, Lindmark AC, et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104(5):1205–1212.
   Web of Science ®Google Scholar
• Holmen N, Isaksson S, Simren M, Sjovall H, Ohman L. CD4+CD25+ regulatory T cells in irritable bowel syndrome patients. Neurogastroenterol Motil. 2007;19(2):119–125.
   Web of Science ®Google Scholar
• Braak B, Klooker TK, Wouters MM, et al. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship? Am J Gastroenterol. 2012;107(5):715–726.
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003;98(7):1578–1583.
   PubMed Web of Science ®Google Scholar
• Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804–811.
   PubMed Web of Science ®Google Scholar
• Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008;57(7):923–929.
   PubMed Web of Science ®Google Scholar
• Kindt S, Van Oudenhove L, Broekaert D, et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil. 2009;21(4):389–398.
   PubMed Web of Science ®Google Scholar
• Chang L, Adeyemo M, Karagiannides I, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol. 2012;107(2):262–272.
   PubMed Web of Science ®Google Scholar
• Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21(1 Pt 1):71–78.
   Web of Science ®Google Scholar
• O’Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000;12(5):449–457.
   PubMed Web of Science ®Google Scholar
• Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008;23(11):1689–1694.
   PubMed Web of Science ®Google Scholar
• Forshammar J, Isaksson S, Strid H, et al. A pilot study of colonic B cell pattern in irritable bowel syndrome. Scand J Gastroenterol. 2008;43(12):1461–1466.
   PubMed Web of Science ®Google Scholar
• Ohman L, Lindmark AC, Isaksson S, et al. B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2009;21(6):644–650. e27.
   Web of Science ®Google Scholar
• De Silva AP, Nandasiri SD, Hewavisenthi J, et al. Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting. Scand J Gastroenterol. 2012;47(6):619–624.
   PubMed Web of Science ®Google Scholar
• Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil. 2006;18(1):6–17.
   PubMed Web of Science ®Google Scholar
• Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci. 1993;38(9):1590–1595.
   PubMed Web of Science ®Google Scholar
• Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137(4):1425–1434.
   PubMed Web of Science ®Google Scholar
• Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693–702.
   PubMed Web of Science ®Google Scholar
• Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59(9):1213–1221.
   PubMed Web of Science ®Google Scholar
• Foley S, Garsed K, Singh G, et al. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology. 2011;140(5):1434–1443. e1.
   Web of Science ®Google Scholar
• Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56(2):203–209.
   PubMed Web of Science ®Google Scholar
• Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol. 2011;106(7):1290–1298.
   PubMed Web of Science ®Google Scholar
• Martinez C, Vicario M, Ramos L, et al. The jejunum of diarrhea- predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol. 2012;107(5):736–746.
   PubMed Web of Science ®Google Scholar
• Roka R, Rosztoczy A, Leveque M, et al. A pilot study of fecal serine- protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007;5(5):550–555.
   Web of Science ®Google Scholar
• Gecse K, Roka R, Ferrier L, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut. 2008;57(5):591–599.
   PubMed Web of Science ®Google Scholar
• Lettesjo H, Hansson T, Peterson C, et al. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Scand J Gastroenterol. 2006;41(1):54–59.
   PubMed Web of Science ®Google Scholar
• Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132(1):26–37.
   PubMed Web of Science ®Google Scholar
• Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007;117(3):636–647.
   PubMed Web of Science ®Google Scholar
• Wang SH, Dong L, Luo JY, et al. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol. 2007;13(45):6041–6047.
   Web of Science ®Google Scholar
• Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 3- hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3(4):349–357.
   PubMed Web of Science ®Google Scholar
• Feldman SA, Eiden LE. The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr Pathol. 2003;14(1):3–23.
   PubMed Web of Science ®Google Scholar
• Ohman L, Stridsberg M, Isaksson S, Jerlstad P, Simren M. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol. 2012;107(3):440–447.
   Web of Science ®Google Scholar
• Bashashati M, Rezaei N, Andrews CN, et al. Cytokines and irritable bowel syndrome: where do we stand? Cytokine. 2012;57(2):201–209.
   PubMed Web of Science ®Google Scholar
• Kraneveld AD, Rijnierse A, Nijkamp FP, Garssen J. Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets. Eur J Pharmacol. 2008;585(2–3):361–374.
   Web of Science ®Google Scholar
• Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7(3):163–173.
   PubMed Web of Science ®Google Scholar
• Matricon J, Meleine M, Gelot A, et al. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther. 2012;36(11–12):1009–1031.
   Web of Science ®Google Scholar
• Scully P, McKernan DP, Keohane J, et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol. 2010;105(10):2235–2243.
   Web of Science ®Google Scholar
• Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006;130(2):304–311.
   PubMed Web of Science ®Google Scholar
• McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther. 2011;33(9):1045–1052.
   Web of Science ®Google Scholar
• Hughes PA, Harrington AM, Castro J, et al. Sensory neuro-immune interactions differ between Irritable Bowel Syndrome subtypes. Gut. Epub July 27, 2012.
   Google Scholar
• Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132(3):913–920.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang Y, Deng Z. Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome. BMC Gastroenterol. 2012;12:91.
   PubMed Web of Science ®Google Scholar
• Macsharry J, O’Mahony L, Fanning A, et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol. 2008;43(12):1467–1476.
   PubMed Web of Science ®Google Scholar
• Bashashati M, Rezaei N, Bashashati H, et al. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2012;24(12): 1102–e566.
   Web of Science ®Google Scholar
• Camilleri M, Katzka DA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;302(10):G1075–G1084.
   PubMed Web of Science ®Google Scholar
• Zucchelli M, Camilleri M, Andreasson AN, et al. Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut. 2011;60(12):1671–1677.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Carlson P, McKinzie S, et al. Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis. Neurogastroenterol Motil. 2011 ;23(10): 935-e398.
   Google Scholar
• Swan C, Duroudier NP, Campbell E, et al. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFa. Gut. Epub June 8, 2012.
   Google Scholar
• van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol. 2005;100(11):2510–2516.
   PubMed Web of Science ®Google Scholar
• Barkhordari E, Rezaei N, Ansaripour B, et al. Proinflammatory cytokine gene polymorphisms in irritable bowel syndrome. J Clin Immunol. 2010;30(1):74–79.
   Web of Science ®Google Scholar
• Villani AC, Lemire M, Thabane M, et al. Genetic risk factors for post- infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138(4):1502–1513.
   PubMed Web of Science ®Google Scholar
• Romero-Valdovinos M, Gudino-Ramirez A, Reyes-Gordillo J, et al. Interleukin-8 and -10 gene polymorphisms in irritable bowel syndrome. Mol Biol Rep. 2012;39(9):8837–8843.
   Web of Science ®Google Scholar
• Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut. 2003;52(1):91–93.
   Google Scholar
• Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol. 2010;106(2):329–336.
   Web of Science ®Google Scholar
• Belmonte L, Beutheu Youmba S, Bertiaux-Vandaele N, et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One. 2012;7(8): e42777.
   Web of Science ®Google Scholar
• Ohman L, Lindmark AC, Isaksson S, et al. Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients. Eur J Gastroenterol Hepatol. 2012;24(4):398–405.
   Web of Science ®Google Scholar
• Schoepfer AM, Schaffer T, Seibold-Schmid B, Muller S, Seibold F. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. NeurogastroenterolMotil. 2008;20(10):1110–1118.
   Web of Science ®Google Scholar
• Langhorst J, Junge A, Rueffer A, et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104(2):404–410.
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Weichenthal M, et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2003;9(4):215–223.
   PubMed Web of Science ®Google Scholar
• Fahlgren A, Hammarstrom S, Danielsson A, Hammarstrom ML. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clin Exp Immunol. 2003;131(1):90–101.
   Web of Science ®Google Scholar
• Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol. 2007;5(5):534–540.
   Web of Science ®Google Scholar
• O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541–551.
   PubMed Web of Science ®Google Scholar
• Corinaldesi R, Stanghellini V, Cremon C, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther. 2009;30(3):245–252.
   PubMed Web of Science ®Google Scholar
• Kokkotou E, Conboy LA, Ziogas DC, et al. Serum correlates of the placebo effect in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(3):285–e81.
   PubMed Web of Science ®Google Scholar